目的 观察选择性支气管动脉灌注吉西他滨、奥沙利铂（GEMOX方案）并联合吉西他滨静脉滴注化疗治疗晚期非小细胞肺癌(NSCLC)的疗效和不良反应.方法对38例晚期NSCLC患者第1d经支气管动脉注入吉西他滨、奥沙利铂,第8d予吉西他滨静脉滴注化疗,21～28 d为一个周期,完成2～3周期后评价其疗效及不良反应.结果38例中完全缓解(CR)0例,部分缓解( PR)23例,总有效率60.5％.主要不良反应为骨髓抑制、消化道反应等,不良反应多为Ⅰ～Ⅱ度.结论基于GE-MOX方案的支气管动脉灌注联合全身化疗治疗晚期非小细胞肺癌疗效好、不良反应可耐受.%Objective To evaluate the efficacy and toxicity of bronchial arterial infusion ( BAI) combined with systemic chemotherapy baaed on GEMOX regimen (gemcitabine plus oxaliplatin) in the treatment of patients with advanced non-small cell cancer ( NSCLC). Methods 38 patients with NSCLC were received GEMOX through the bronchial artery on day 1 and follow by systemic chemotherapy of gemcitabine on day 8 for 2 - 3 cycles, which were repeated every 21 - 28 days. The positive response and adverse effects were assessed. Results In 38 patients,complete response (CR) were obtained in0 and partial response (PR) in 23 cases,with overall response , rate (RR) of 60.5%. The main toxicity included mild myelosuppression,gastrointestinal effects. Conclusions The combination of BAI and systemic chemotherapy based on GEMOX regimen is highly effective for advanced NSCLC,and causes mild adverse effects.
展开▼
